Zobrazeno 1 - 10
of 706
pro vyhledávání: '"U Hedner"'
Publikováno v:
Haemophilia. 15:1318-1326
Summary. Replacement therapy with factor VIII (FVIII) and factor IX (FIX) is routinely used in haemophilia patients with haemophilia A and B, respectively, while recombinant activated FVII (rFVIIa) has proven to induce haemostasis in haemophilia pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cd18bf8fdd354472b92d429a7991606
https://doi.org/10.1111/j.1365-2516.2009.02073.x
https://doi.org/10.1111/j.1365-2516.2009.02073.x
Autor:
J A Quiroga, Maria Luisa Manzano, Elena Rodríguez-Iñigo, V Carreño, J F Tomás, U Hedner, F Manzarbeitia, Javier Bartolomé, H Oliva, A. Suarez, Carlos Arocena
Publikováno v:
Blood Coagulation and Fibrinolysis. 12:193-199
Factor VII (FVII) plasma levels in patients with liver disease may be below the normal range. However, no data are available on FVII expression in liver biopsies from patients with liver diseases other than cirrhosis. We have analyzed the expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02c49fc0be282d4c94cdc7aef333cd1
https://doi.org/10.1097/00001721-200104000-00005
https://doi.org/10.1097/00001721-200104000-00005
Publikováno v:
Blood Coagulation & Fibrinolysis. 11:S95-S99
Patients with liver cirrhosis and diminished prothrombin activity (PA) have decreased levels of factor (F)VII coagulation activity (FVII:C) and an increased bleeding tendency. Whether this is also true of cirrhotic patients with normal PA is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eb66d40912821a02c9b32ce0edeaa21
https://doi.org/10.1097/00001721-200004001-00018
https://doi.org/10.1097/00001721-200004001-00018
Publikováno v:
Blood Coagulation & Fibrinolysis. 9:741-748
Vitamin K antagonists are most commonly used in long-term thrombosis prophylaxis and the use in patients with cardiovascular disease seems to be increasing. By interfering with the normal hemostatic mechanism, an increased risk of bleeding will arise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7548064c236291a38d966342434e520d
https://doi.org/10.1097/00001721-199811000-00003
https://doi.org/10.1097/00001721-199811000-00003
Publikováno v:
Blood. 91:1609-1615
Antitissue factor antibody attenuated the coagulopathic and lethal responses to LD100Escherichia coli, whereas active site inhibited factor Xa inhibited only the coagulopathic response. In this study, we wished to determine: (1) whether active site i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b27adfc0eb961dae9454cd0dde38bf5
https://doi.org/10.1182/blood.v91.5.1609
https://doi.org/10.1182/blood.v91.5.1609
Autor:
U, Hedner
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e18b145e53e72f797d999d06da29e3f
https://pubmed.ncbi.nlm.nih.gov/22335449
https://pubmed.ncbi.nlm.nih.gov/22335449
Autor:
E C, Rodriguez-Merchan, V, Jimenez-Yuste, J A, Aznar, U, Hedner, K, Knobe, C A, Lee, R, Ljung, F, Querol, E, Santagostino, L A, Valentino, A, Caffarini
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17
Haemarthroses (intra-articular haemorrhages) are a frequent finding typically observed in patients with haemophilia. Diagnosis and treatment of these bleeding episodes must be delivered as early as possible. Additionally, treatment should ideally be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ebb9607f6134401ef9e7a7f94f1cbcea
https://pubmed.ncbi.nlm.nih.gov/21819491
https://pubmed.ncbi.nlm.nih.gov/21819491
Autor:
D F, Brophy, E J, Martin, J, Christian Barrett, M E, Nolte, J G, Kuhn, P M, Gerk, M E, Carr, H, Pelzer, H, Agersø, M, Ezban, U, Hedner
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(5)
Recombinant FVIIa is a haemostatic agent administered to patients with severe FVIII or FIX deficiency with inhibitors. Although rFVIIa is effective at stopping bleeding, a reliable assay to monitor its effect is lacking. To characterize the pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::05e28bce6ea295954f68a6362ee70138
https://pubmed.ncbi.nlm.nih.gov/21362113
https://pubmed.ncbi.nlm.nih.gov/21362113
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(1)
This review describes the background for the development of recombinant FVIIa (rFVIIa; NovoSeven) for use in haemophilic patients with inhibitors. The first proof of principle for using pharmacological doses of FVIIa as a haemostatic agent was obtain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7248d8e7aec055500617aa28d3f8d3a1
https://pubmed.ncbi.nlm.nih.gov/20609014
https://pubmed.ncbi.nlm.nih.gov/20609014